Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential of 4-azasteroids as 5α-reductase inhibitors for treating hirsutism, reporting their promising effects in animal studies but noting no clinical trials have been conducted yet.

This study generated a pharmacophoric model for both isoforms of steroidal 5α-reductase using 6-azasteroids, providing a structural framework for designing new inhibitors.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

This study comprehensively compared different crystalline forms of finasteride, including the new finasteride DMF solvate hemihydrate, to better understand their structural characteristics and intermolecular interactions.

This study observed that finasteride and spironolactone both led to a similar significant, but limited, improvement in hirsutism despite their differing effects on androgen levels.

This review discusses the latest understanding of androgenetic alopecia, including stem cell niches in hair follicles, and highlights emerging treatments like growth factors and platelet-rich plasma without new clinical findings.

This study found that solid-state NMR combined with X-ray techniques provided critical insights into the structure and solvation of finasteride polymorphs, identifying gaps in existing patent characterizations.

Finasteride can cause enlarged breasts.

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

This study found that overexpression of PTHrP in mice chondrocytes led to short-limbed dwarfism and delays in endochondral ossification, highlighting PTHrP's role in inhibiting chondrocyte differentiation.

This study found significant species differences in the enzyme activity and inhibitor affinities of prostatic 5α-reductases from rats, dogs, and humans, with variable potencies for different 3-oxo-4-azasteroid inhibitors across species.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

This report describes three cases of white piedra of scalp hair, identifying Trichosporon inkin and Trichosporon mucoides as the fungi responsible, which are uncommon causes of this condition.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This study found that intracrine androgen signaling via 5α-reductase is essential for optimal endometrial decidualization and vascular development during this process in mice.

This study found that intracrine androgen signaling, mediated by steroid 5α-reductase, is essential for optimal decidualization and vascular development in the endometrium during pregnancy, indicating potential targets for improving age-related fertility issues.

The meeting showcased rare skin disease cases, highlighting the need for accurate diagnosis and treatment.

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This study reported that oral finasteride 1.25mg/day slowed hair loss and increased hair growth in Korean men with androgenetic alopecia over 8 months, with minimal side effects.

This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.

Finasteride effectively blocks rat enzymes, but with varying methods and strength.

This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.